Emmaus Life Sciences Q3 net revenue up 9% to $5.5M; net income $1.8M vs $0.07M YoY

Emmaus Life Sciences, Inc.

2024-Q3 EPS reported -$0.07 revenue$13,361,000

Net revenues $5.5M (+9% YoY) driven by Middle East sales; U.S. sales fell due to generic L-Glutamine competition.
Q3 income from operations $0.8M (vs $0.02M YoY); net income $1.8M ($0.03 EPS) vs $0.07M.
Nine-month net loss $4.7M ($0.07 per share) vs $4.9M loss in prior year; revenue down 41% due to inventory shortages.
Cash at Sept 30, 2024: $1.3M, down from $2.5M at Dec 31, 2023.
CEO expects full-year results materially lower than 2023; generic competition may affect future Endari sales.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.